Northeastern Section of American Chemical Society (NESACS) and Chinese -American BioMedical Association (CABA) are organizing a scientific symposium on Saturday, May 22 at Holiday Inn of Woburn, MA (15 Middlesex Canal Park Road). This symposium will feature "Drug R&D in China: Status, Opportunity, International Collaboration and Challenges". Comparing to the well-established Chinese Pharmaceutical CRO services sector, China's innovative drug R&D has shown its momentum only in recent several years. Prominent academic professors and seasoned industrial scientists and executives from both China and US will share their views on China's drug R&D and the impact to the global pharmaceutical industry. Don't miss this unique opportunity to learn about China's drug R&D status and to network with leaders in this field.

NESACS and CABA members will enjoy a discount rate ($30 for ACS members, $20 for CABA members, $35 for non-members) to attend this symposium.

Pre-registration is required. Please register before May 19 by accepting the Evite invitation below. Please put down your full name and affiliation so that a proper nametag can be prepared for you by the organizers beforehand.
http://www.evite.com/app/publicUrl/SIEVVUIRCDIGGZEPGSVP/ChinaRnD

Attached is the flyer. For more information and updates, please go to www.NESACS.org.

DRUG R&D IN CHINA - Status, Opportunity, International Collaboration and Challenges

Organizer by
Northeastern Section of American Chemical Society (NESACS)
Chinese-American BioMedical Association (CABA)

Saturday, May 22nd, 2010
Holiday Inn (15 Middlesex Canal Park Road, Woburn, MA)

Program

8:30~9:00 Registration

9:00~9:05 Welcome
Dr. Liming Shao (Chair of Medicinal Chemistry, NESACS)

9:05~9:15 Opening Remarks
Dr. John Neumeyer (Harvard Medical School, McLean Hospital)

9:15~12:00 Session I
Drug discovery in China and Chinese pharmaceutical industry - Status and opportunity, Chair, Dr. Yuan Wang (Director, Discovery, Oncology-PCU, Eisai)

9:20~10:00 Drug Discovery in China - An Insider’s View
Dr. Jingkang Shen (Professor, Shanghai Institute of Materia Medica, Chinese Academy of Science)

10:00~10:30 Trends of World Drug R&D - A Global View of Chinese Pharmaceutical Industry, Christopher-Paul Milne, DVM, MPH, JD (Associate Director, Center for the Study of Drug Development, Tufts University)

10:30~10:45 Break

10:45~11:15 New drug discovery: starting from the old ones, Dr. Hongbing Sun (Professor of Medicinal Chemistry, Director of Center of Drug Discover, China Pharmaceutical University)

11:15~11:45 Build up discovery capability, a story from a small biotech company, Dr. Michael Song (COO/CSO, KBP Bioscience, China)

11:45~1:00 Lunch

Session II
1:00-3:00 Leveraging China’s drug discovery through international collaboration, Chair, Dr. Zhijian Lu (Director, Extramural Partnered Research, Asia, Global Biotherapeutics Technologies, Pfizer)

1:00~1:30pm Building a library of authenticated, quality controlled, source-documented Traditional Chinese Medicine (TCM) plants at Harvard Medical School: an international collaboration to identify new therapeutic opportunities, Dr. Bruce Littlefield (Harvard University, Medical School)

1:30~2:00pm Current Status and Future Directions of Simcere’s Pharmaceutical R&D, Dr. Peng Wang (CSO, Simcere Pharmaceutical Group)

2:00~2:30pm Partnering for Success: An Overview of Pfizer’s R&D Innovation Efforts in China, Dr. Yuan-Hua Ding (Director, Head of External R&D Innovation – Asia, Pfizer Biotherapeutics Research and Development)

2:30~3:00pm Establishment of a world-leading Oncology R&D innovation group in Shanghai: the AstraZeneca experience, Dr. Luciene Ronco (Global Director of Discovery Medicine and Translational Science, AstraZeneca)

3:00~3:30 Panel Discussion, Moderator, Dr. Chaoyang Dai, (President, CABA)

3:30~4:00 Break

4:00~6:00 Session III
Challenges and opportunities Drug R&D in China. Chair, Dr. Yibin Xiang (Sr. Director, Medicinal Chemistry, Genzyme)

4:00~4:30 It is all possible - from Tianyuan’s success story to look at opportunity in drug R&D in China, Dr. Sam Liao (Head of Business Development & Licensing, Novartis Vaccines & Diagnostics)

4:30~5:00 Development of Multi-Targeted siRNA Therapeutics with Nanoparticle-Enhanced Delivery Systems, Patrick Y. Lu, Ph.D. (Founder, President and CEO of Sirnaomics, Inc)

5:00~5:30 Is IP still an issue for drug R&D in China? - Recent changes and progress for IP protection in China, Philip Zhang, Ph.D. (Esq. Co-Founder of Principal Milstein Zhang & Wu LLC)

5:30~6:00 To pursue IP protection in China - understanding the commons and differences of IP protection between US and China through case studies, Michael McGurk, Partner (Finnegan)

6:00~7:00 Social Hour Reception (Sponsored by Sundia MediTech Company)